SAFE Drugs Act

The 119th Congress will start 2026 with a pharmaceutical and medical product supply chain under unprecedented strain, defined by globalized manufacturing, explosive growth in small-package imports, sophisticated counterfeiters, and a drug shortage crisis that has reshaped how medicines reach patients. While the United States’ drug supply chain remains the gold standard for safety, outdated authorities, resource gaps, and enforcement loopholes are being exploited by bad actors at the expense of public health. The SAFE Drugs Act (H.R.6509) would require 503B compounding facilities to be inspected by the FDA before shipping products. ADAP Advocacy urges patient advocates and public policy stakeholders to express support for the SAFE Drugs Act!